Volume 11, Issue 3 (Summer 2022)
J Occup Health Epidemiol 2022, 11(3): 180-186 |
Back to browse issues page
Zahra Abdolahinia1 
, Moghaddameh Mirzaee2 , Hamid Pakmanesh3 , Azam Bazrafshan4 , Mehdi Shafiei Bafti5 , Armita Shahesmaeili * 6
, Moghaddameh Mirzaee2 , Hamid Pakmanesh3 , Azam Bazrafshan4 , Mehdi Shafiei Bafti5 , Armita Shahesmaeili * 6
1- Ph.D Student in Epidemiology, HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
2- Associate Prof., Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
3- Associate Prof., Dept., of Urology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
4- Ph.D in Medical Library and Information Sciences, Kerman Population-Based Cancer Registry (KPBCR), Deputy of Health, Kerman University of Medical Sciences, Kerman, Iran; HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman, Iran.
5- MD, MPH, Head of Communicable Diseases Department, Deputy of Health, Kerman University of Medical Sciences, Kerman, Iran.
6- 6. Associate Prof., HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. , a.shahesmaeili@gmail.com
2- Associate Prof., Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
3- Associate Prof., Dept., of Urology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
4- Ph.D in Medical Library and Information Sciences, Kerman Population-Based Cancer Registry (KPBCR), Deputy of Health, Kerman University of Medical Sciences, Kerman, Iran; HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman, Iran.
5- MD, MPH, Head of Communicable Diseases Department, Deputy of Health, Kerman University of Medical Sciences, Kerman, Iran.
6- 6. Associate Prof., HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. , a.shahesmaeili@gmail.com
Article history
Received: 2022/04/6
Accepted: 2022/08/6
ePublished: 2022/12/17
Accepted: 2022/08/6
ePublished: 2022/12/17
Subject:
Epidemiology
Abstract: (694 Views)
Background: Bladder cancer is the 10th most common cancer worldwide. We aimed to assess the prevalence of bladder cancer in the Kerman Province, in southeast Iran.
Materials and Methods: In this cross-sectional study, we used data on 1272 patients with bladder cancer registered in the Kerman population-based cancer registry from 2014 to 2017. There were two parts of data including observed data, including those cases whose information was recorded by the cancer registry, and the unobserved part, including cases before the registry department, was established, to calculate the complete prevalence. The latter was estimated using modeling to be included in the prevalence calculation. The complete prevalence of three-, five-, ten-, and twenty-year of bladder cancer up to the end of 2017 was calculated using rprev package.
Results: A total of 185 (14.54%) women and 1,087 (85.45%) men were recruited. The overall three-, five-, ten-, and twenty-year prevalence of bladder cancer at the end of 2017 was 26.54, 43.46, 80.3, and 142.36 per 100,000 inhabitants, respectively. The prevalence was estimated to be at its lowest rate among both males and females under the age of 45, and at its highest rate among those over 61 and older. In all age groups, males were affected more than females.
Conclusion: The prevalence of bladder cancer in the Kerman Province was higher than the national average and increased with age. Regarding the aging population, policies and programs for prevention, early intervention, and awareness-raising in the community about this cancer are essential.
Materials and Methods: In this cross-sectional study, we used data on 1272 patients with bladder cancer registered in the Kerman population-based cancer registry from 2014 to 2017. There were two parts of data including observed data, including those cases whose information was recorded by the cancer registry, and the unobserved part, including cases before the registry department, was established, to calculate the complete prevalence. The latter was estimated using modeling to be included in the prevalence calculation. The complete prevalence of three-, five-, ten-, and twenty-year of bladder cancer up to the end of 2017 was calculated using rprev package.
Results: A total of 185 (14.54%) women and 1,087 (85.45%) men were recruited. The overall three-, five-, ten-, and twenty-year prevalence of bladder cancer at the end of 2017 was 26.54, 43.46, 80.3, and 142.36 per 100,000 inhabitants, respectively. The prevalence was estimated to be at its lowest rate among both males and females under the age of 45, and at its highest rate among those over 61 and older. In all age groups, males were affected more than females.
Conclusion: The prevalence of bladder cancer in the Kerman Province was higher than the national average and increased with age. Regarding the aging population, policies and programs for prevention, early intervention, and awareness-raising in the community about this cancer are essential.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [DOI] [PMID]
2. Afsharmoghadam N, Haghighatian Z, Mazdak H, Mirkheshti N, Mehrabi Koushki R, Alavi SA. Concentration-dependent effects of Curcumin on 5-fluorouracil efficacy in bladder cancer cells. Asian Pac J Cancer Prev. 2017;18(12):3225-30. [DOI] [PMID] [PMCID]
3. World Health Organization. Global Cancer Observation, Cancer today. Geneva, Switzerland: World Health Organization; 2020. Available from: https://gco.iarc.fr/today/home [Report]
4. Richters A, Aben KKH, Kiemeney LALM. Kiemeney, The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895-1904. [DOI] [PMID] [PMCID]
5. Cassell A, Yunusa B, Jalloh M, Mbodji MM, Diallo A, Ndoye M, et al. Non-muscle invasive bladder cancer: a review of the current trend in Africa. World J Oncol. 2019;10(3):123-31. [DOI] [PMID] [PMCID]
6. Ahrens W, Pigeot I. Handbook of epidemiology. 2nd ed. Springer; 2014. [DOI]
7. Capocaccia R, Colonna M, Corazziari I, De Angelis R, Francisci S, Micheli A, et al. Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol. 2002;13(6):831-9. [DOI] [PMID]
8. Gail MH, Kessler L, Midthune D, Scoppa S. Two approaches for estimating disease prevalence from population‐based registries of incidence and total mortality. Biometrics. 1999;55(4):1137-44. [DOI] [PMID]
9. Colonna M, Hedelin G, Esteve J, Grosclaude P, Launoy G, Buemi A, et al. National cancer prevalence estimation in France. Int J Cancer. 2000;87(2):301-4. [PMID]
10. Verdecchia A, Capocaccia R, Egidi V, Golini A. A method for the estimation of chronic disease morbidity and trends from mortality data. Stat Med. 1989;8(2):201-16. [DOI] [PMID]
11. Wall S. Cancer Epidemiology: Principles and Methods. Isabel dos Santos Silva. IARC Press, Lyon, France, 1999. No. of pages: ix+ 442. Price:£ 40.00 ISBN 92-832-0405-0. Stat Med. 2001;20(5):821-2. [DOI:10.1002/sim.759]
12. Sajadi A, Zahedi MJ, Darvish Moghadam S, Nouraie M, Alimohammadian M, Ghorbani A, et al. The first population-based cancer survey in Kerman Province of Iran. Iran J Public Health. 2007;36(4):26-34. [Article]
13. Pakzad R, Mohammadian-Hafshejani A, Mohammadian M, Pakzad I, Safiri S, Khazaei S, et al. Incidence and mortality of bladder cancer and their relationship with development in Asia. Asian Pac J Cancer Prev. 2015;16(16):7365-74. [DOI] [PMID]
14. Shahesmaeili A, Malekpour Afshar R, Sadeghi A, Bazrafshan A. Cancer incidence in Kerman Province, Southeast of Iran: report of an ongoing population-based cancer registry, 2014. Asian Pac J Cancer Prev. 2018;19(6):1533-41. [DOI] [PMID] [PMCID]
15. Malakootian M, Mohammadi Senjedkooh S. Quality Assessment of SIRJAN Plain Groundwater Resources to Evaluate Their Contamination to Heavy Metals at 2014. J Torbat Heydariyeh Uni Med Sci. 2014;2(2):31-9. [Article]
16. Mortazavi N, Asadikaram G, Ebadzadeh MR, Kamalati A, Pakmanesh H, Dadgar R, et al. Organochlorine and organophosphorus pesticides and bladder cancer: A case‐control study. J Cell Biochem. 2019;120(9):14847-59. [DOI] [PMID]
17. Keyghobadi N, Rafiemanesh H, Mohammadian-Hafshejani A, Enayatrad M, Salehiniya H. Epidemiology and trend of cancers in the province of Kerman: southeast of Iran. Asian Pac J Cancer Prev. 2015;16(4):1409-13. [DOI] [PMID]
18. Li J, Smith A, Crouch S, Oliver S, Roman E. Estimating prevalence of haematological malignancies using data from the Haematological Malignancy Research Network (HMRN). Cancer Causes Control. 2016;27(8):1019-26. [DOI] [PMID] [PMCID]
19. Zhang AS, Ostrom QT, Kruchko C, Rogers L, Peereboom DM, Barnholtz-Sloan JS. Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. Neuro Oncol. 2017;19(5):726-35. [DOI] [PMID] [PMCID]
20. Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12(6):520-7. [DOI] [PMID] [PMCID]
21. Mazdak H, Tolou-Ghamari Z. Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran. Arab J Urol. 2018;16(2):206-10. [DOI] [PMID] [PMCID]
22. The :union: for International Cancer Control. Globocan 2020: New Global Cancer Data. Geneva, Switzerland: The :union: for International Cancer Control; 2020.
23. World Health Organization. Cancer. Geneva, Switzerland: World Health Organization; 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer [Report]
24. Kazemi M, Bazyar M, Naghizadeh MM, Dehghan A, Sedigh Rahimabadi M, Rostami Chijan M, et al. Lipid Profile in Opium Users: Results of Fasa PERSIAN Cohort Study, First Phase. [Internet]. 2020. doi: 10.21203/rs.3.rs-98847/v1 [DOI]
25. Abdolahinia Z, Pakmanesh H, Mirzaee M, Bazrafshan A, Shafiei Bafti M, Shahesmaeili A. Opium and Cigarette Smoking are Independently Associated with Bladder Cancer: The Findings of a Matched Case-Control Study. Asian Pac J Cancer prev. 2021;22(10):3385-91. [DOI] [PMID] [PMCID]
26. Kalan Farmanfarma K, Mahdavifar N, Salehiniya H. Bladder cancer in Iran: an epidemiological review. Res Rep Urol. 2020;12:91-103. [DOI] [PMID] [PMCID]
27. World Health Organization. International Agency for Research Cancer. Cancer today. Geneva, Switzerland: World Health Organization; 2020. Available from: https://gco.iarc.fr/today/home [Report]
28. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8(1):15. [DOI] [PMID] [PMCID]
29. Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, et al. Cancer incidence in five continents Vol XI. IARC Scientific Publication No. 166. Lyon: International Agency for Research on Cancer; 2021.
30. World Health Organization. International Agency for Research Cancer. Bladder cancer. Geneva, Switzerland: World Health Organization; 2020. Available from: https://www.iarc.who.int/cancer-type/bladder-cancer/ [Report]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |